{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Table 3:', 'Table of Events (Continued)', 'Post-Treatment', 'Screening', 'Placebo-Controlled Phase', 'Apremilast Extension Phase', 'Observational Follow-upd', 'Baseline', 'Visit Number', '1', '2', '3', '4', '5', '6', '7', '8', '9/ETC', '56 (or 4 weeks after study', '-35 to 0', '0', '2', '4', '16', '20', '32', '44', '52', 'discontinuation)', 'Week', 'days', '(Day 1)', '(3 days)', '( 3 days)', '(=3 days)', '( 4 days)', '( 4 days)', '( 4 days)', '( 4 days)', 'Health-related Quality of Life and Efficacy Assessments', 'DLQI', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'sPGA of Visible', '-', '-', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Location', 'ScPGAk', '-', '-', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Nail Assessment', '-', '-', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'NAPSI', '-', '-', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Modified sPGA-Gk', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'PPPGAK', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'Itch NRS', '-', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'Skin Discomfort/Pain', '-', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'VAS', 'PASI', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'BSA', '-', 'X', 'X', 'X', 'X', 'X', 'X', '-', 'X', '-', 'EQ-5D', '-', 'X', '-', '-', 'X', '-', '-', '-', 'X', '-', 'PNQ', '-', 'X', '-', '-', '-', '-', '-', '-', '-', '-', 'PBQ', '-', '-', '-', 'X', 'X', '-', 'X', '-', 'X', '-', 'WPAI: PSO', '-', 'X', '-', '-', 'X', '-', '-', '-', 'X', '-', 'Photography\"', '-', 'X', '-', '-', 'X', '-', 'X', '-', 'X', '-', 'Confidential and Proprietary', '30', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Table 3:', 'Table of Events (Continued)', 'Post-Treatment', 'Screening', 'Placebo-Controlled Phase', 'Apremilast Extension Phaseb', 'Observational Follow-upd', 'Baseline', 'Visit Number', '1', '2', '3', '4', '5', '6', '7', '8', '9/ETC', '56 (or 4 weeks after study', '-35 to 0', '0', '2', '4', '16', '20', '32', '44', '52', 'discontinuation)', 'Week', 'days', '(Day 1)', '(+3 days)', '( 3 days)', '( 3 days)', '( 4 days)', '( 4 days)', '( 4 days)', '( 4 days)', '-', '-', '-', '-', 'Dispense IP', 'X', 'X', 'X', 'X', 'X', 'X', 'Return and Count IP', '-', '-', '-', '-', 'X', 'X', 'X', 'X', 'X', 'X', 'Tablets', 'Abbreviations: BMI = body mass index; BSA = body surface area;', 'DLQI = Dermatology Life Quality Index; EQ-5D = European Quality of Life 5-', 'Dimension; FCBP = females of childbearing potential; IP = investigational product; NAPSI = Nail Psoriasis Severity Index; PASI = Psoriasis Area Severity Index; PBQ = Patient', 'Benefit Questionnaire; PNQ = Patient Needs Questionnaire; PPPGA = Palmoplantar Psoriasis Physicians Global Assessment; NRS = Numeric Rating Scale; ScPGA = Scalp', 'Physician Global Assessment; sPGA = static Physicians Global Assessment; sPGA-G = static Physicians Global Assessment of Genitalia; VAS = Visual Analog Scale;', 'WPAI:PSO = Work Productivity and Activity Impairment Questionnaire: Psoriasis.', 'a Visits in the Placebo-controlled Phase to be performed 3 days.', 'b Visits in the Apremilast Extension Phase to be performed 4 days.', 'c Visit 9 will serve as the Early Termination Visit for any subject who prematurely discontinues from the study, prior to Week 52. All subjects who complete the study or', 'discontinue the study early will be asked to enter the Four-week Post-treatment Observational Follow-up Phase.', 'd', 'Post-treatment observational follow-up will be conducted by telephone.', 'e Written informed consent will be obtained by the Principal Investigator or designee prior to initiation of any study procedures, including washouts from prior medications.', 'f Adverse event review should include new or worsening psychiatric symptoms, suicidal ideation, suicidal attempt, severe diarrhea, nausea and vomiting, and unexplained and', 'clinically significant weight loss. See Section 6.5.', 'g Females of childbearing potential (FCBPs) only. Serum pregnancy tests are performed at Screening, and Early Termination Visit/Last Treatment Visit. Urine pregnancy test kit', 'will also be provided to the site and performed at baseline prior to randomization. The Investigator will educate all FCBP about the different options of contraceptive methods', 'and their correct use at Screening and Baseline visits. The subject will be reeducated every time their contraceptive measures/methods or their ability to become pregnant', 'changes. A pregnancy test(s) should be administered if the FCBP subject misses a menstrual period.', 'h', 'Laboratory assessments will include routine/standard chemistry and hematology panel of tests. A lipid panel will be included in the standard chemistry panel. If screening', 'laboratory assessments are within 7 days of Baseline (Week 0), laboratory assessment does not need to be repeated at Baseline (Week 0). For females of childbearing potential', 'urine pregnancy test will be performed at Baseline (Week 0) to confirm subject eligibility (negative results required for IP administration).', 'j Subject assessments must be completed in the following order: DLQI, Itch NRS, Skin Discomfort/Pain VAS, EQ-5D, PNQ/PBQ, and WPAI: PSO, as scheduled in the Table of', 'Events.', 'k All manifestations should be assessed in all subjects at all visits, so that improvement, worsening, or new onset of any of these manifestations can be assessed.', '1', 'Nail assessments will evaluate presence of nail psoriasis, defined as onycholysis and onychodystrophy.', 'm Photographs will be obtained from subjects who provide separate consent to be photographed and at select sites only.', 'Confidential and Proprietary', '31', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']\n\n###\n\n", "completion": "END"}